2,011 reports of this reaction
3.1% of all LENVATINIB reports
#7 most reported adverse reaction
BLOOD PRESSURE INCREASED is the #7 most commonly reported adverse reaction for LENVATINIB, manufactured by Eisai Inc.. There are 2,011 FDA adverse event reports linking LENVATINIB to BLOOD PRESSURE INCREASED. This represents approximately 3.1% of all 64,104 adverse event reports for this drug.
Patients taking LENVATINIB who experience blood pressure increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD PRESSURE INCREASED is moderately reported among LENVATINIB users, representing a notable but not dominant share of adverse events.
In addition to blood pressure increased, the following adverse reactions have been reported for LENVATINIB:
The following drugs have also been linked to blood pressure increased in FDA adverse event reports:
BLOOD PRESSURE INCREASED has been reported as an adverse event in 2,011 FDA reports for LENVATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD PRESSURE INCREASED accounts for approximately 3.1% of all adverse event reports for LENVATINIB, making it a notable side effect.
If you experience blood pressure increased while taking LENVATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.